Putting Biogen's Aduhelm crisis behind him, Al Sandrock grabs CEO role at gene therapy player to lead turnaround mission - Endpoints News

Al Sandrock’s re-entry back to biotech comes just as abruptly as his last exit. The Biogen vet — who retired last November as R&D chief after steering the Alzheimer’s drug aducanumab (now Aduhelm) straight into a storm of controversy surrounding its approval …

AbbVie’s first TV commercial for Vuity eye drops for age-related vision loss stops surprised people in their tracks. Wait, what? the middle-aged, eyeglass-wearing actors say when they hear about the… [+466 chars]

full article...